Divis Laboratories Financials
| DIVISLAB | 6,173 220.90 3.71% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 19.9 B | 18.3 B |
|
|
Divis | Select Account or Indicator |
Understanding current and past Divis Laboratories Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Divis Laboratories' financial statements are interrelated, with each one affecting the others. For example, an increase in Divis Laboratories' assets may result in an increase in income on the income statement.
Please note, the presentation of Divis Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Divis Laboratories' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Divis Laboratories' management manipulating its earnings.
Divis Laboratories Stock Summary
Divis Laboratories competes with Paramount Communications, Pritish Nandy, OnMobile Global, Dhunseri Investments, and Praxis Home. Divis Laboratories is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE361B01024 |
| Business Address | Divi Towers, Hyderabad, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.divislabs.com |
| Phone | 91 40 6696 6300 |
You should never invest in Divis Laboratories without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Divis Stock, because this is throwing your money away. Analyzing the key information contained in Divis Laboratories' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Divis Laboratories Key Financial Ratios
Divis Laboratories' financial ratios allow both analysts and investors to convert raw data from Divis Laboratories' financial statements into concise, actionable information that can be used to evaluate the performance of Divis Laboratories over time and compare it to other companies across industries.| Revenue | 78.45 B | ||||
| Gross Profit | 44.96 B | ||||
| EBITDA | 25.43 B | ||||
| Net Income | 16 B | ||||
| Cash And Equivalents | 1.41 B |
Divis Laboratories Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 85.4B | 107.7B | 133.7B | 144.4B | 154.7B | 162.4B | |
| Other Current Liab | 5.4M | 3.3B | 3.8B | 3.4B | 10.8B | 11.3B | |
| Net Debt | (43M) | (20.3B) | (12.1B) | (1.7B) | (3.6B) | (3.4B) | |
| Cash | 431.5M | 20.3B | 12.1B | 1.7B | 3.6B | 2.4B | |
| Net Receivables | 16.0B | 16.8B | 24.2B | 17.9B | 20.9B | 21.9B | |
| Inventory | 18.6B | 21.5B | 28.3B | 30.0B | 31.8B | 33.4B | |
| Other Current Assets | 991.5M | 19.4B | 27.8B | 1.3B | 7.0B | 5.4B | |
| Total Liab | 12.3B | 14.8B | 16.5B | 16.7B | 19.0B | 19.9B | |
| Total Current Assets | 46.8B | 61.7B | 83.5B | 93.1B | 96.8B | 101.6B | |
| Accounts Payable | 5.9B | 7.6B | 8.0B | 7.6B | 6.4B | 4.3B | |
| Short Term Debt | 343.8M | 11.4M | 8.2M | 10M | 9M | 8.6M | |
| Retained Earnings | 57.9B | 76.0B | 99.9B | 109.6B | 117.9B | 62.4B | |
| Other Liab | 2.3B | 2.9B | 3.6B | 4.5B | 5.2B | 5.4B | |
| Net Tangible Assets | 69.5B | 73.1B | 92.9B | 117.2B | 134.8B | 70.0B | |
| Other Assets | 1.5B | 1.8B | 1.6B | 956.7M | 1.1B | 1.7B | |
| Intangible Assets | 36M | 49.5M | 74.9M | 52.8M | 40M | 50.7M | |
| Long Term Debt Total | 44.7M | 36.9M | 28.7M | 27.7M | 31.9M | 21.7M | |
| Net Invested Capital | 73.4B | 92.9B | 117.3B | 127.7B | 135.7B | 106.5B | |
| Net Working Capital | 37.5B | 50.6B | 71.6B | 82.1B | 84.0B | 63.3B |
Divis Laboratories Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 55.4M | 3.9M | 3.7M | 6.7M | 30M | 28.5M | |
| Total Revenue | 52.9B | 68.6B | 88.0B | 77.7B | 78.5B | 45.6B | |
| Gross Profit | 31.8B | 45.3B | 58.3B | 47.1B | 32.4B | 29.5B | |
| Operating Income | 17.7B | 26.7B | 36.9B | 23.7B | 18.3B | 19.9B | |
| Ebit | 17.7B | 26.7B | 36.9B | 23.7B | 21.7B | 20.1B | |
| Ebitda | 19.6B | 29.2B | 40.0B | 27.1B | 25.4B | 21.6B | |
| Cost Of Revenue | 21.1B | 23.2B | 29.7B | 30.5B | 46.0B | 48.3B | |
| Income Before Tax | 18.2B | 26.7B | 36.8B | 23.7B | 21.6B | 13.7B | |
| Net Income | 13.8B | 19.8B | 29.6B | 18.2B | 16B | 10.8B | |
| Income Tax Expense | 4.4B | 6.8B | 7.2B | 5.5B | 5.6B | 3.1B | |
| Research Development | 111.4M | 149.7M | 202.9M | 300.5M | 790M | 829.5M | |
| Tax Provision | 4.4B | 6.8B | 7.2B | 5.5B | 5.6B | 5.4B | |
| Interest Income | 1.8B | 52.5M | 8M | 3.4B | 3.0B | 3.2B | |
| Net Interest Income | (4.8M) | (8.7M) | (8M) | (6.7M) | (30M) | (28.5M) |
Divis Laboratories Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Divis Laboratories. It measures of how well Divis is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Divis Laboratories brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Divis had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Divis Laboratories has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (915.2M) | (2.8B) | (6.8B) | (1.7B) | (1.8B) | (1.9B) | |
| Change In Cash | 410.5M | 19.9B | (8.2B) | (10.5B) | 1.9B | 2.0B | |
| Free Cash Flow | 327.3M | 10.4B | 12.0B | 19.9B | 2.6B | 4.7B | |
| Depreciation | 1.9B | 2.6B | 3.1B | 3.4B | 3.8B | 4.0B | |
| Other Non Cash Items | (5.7B) | (7.1B) | (7.1B) | (6.7B) | (1.1B) | (1.2B) | |
| Dividends Paid | 3.2B | 10.2B | 5.3B | 8.0B | 8.0B | 8.4B | |
| Capital Expenditures | 11.8B | 9.1B | 7.1B | 4.7B | 10.0B | 10.5B | |
| Net Income | 18.2B | 26.7B | 36.8B | 23.7B | 16B | 13.6B | |
| End Period Cash Flow | 431.5M | 20.3B | 12.1B | 1.7B | 3.6B | 2.3B | |
| Investments | 10.6B | 9.3B | (15.5B) | (27.1B) | (2.7B) | (2.8B) | |
| Net Borrowings | 776M | (612M) | (340.2M) | (11.4M) | (10.3M) | (9.7M) | |
| Change To Netincome | (675M) | (1.3B) | (288.7M) | 102.9M | 92.6M | 97.2M |
Divis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Divis Laboratories's current stock value. Our valuation model uses many indicators to compare Divis Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Divis Laboratories competition to find correlations between indicators driving Divis Laboratories's intrinsic value. More Info.Divis Laboratories Limited is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.66 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Divis Laboratories Limited is roughly 1.53 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Divis Laboratories by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Divis Laboratories' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Divis Laboratories Systematic Risk
Divis Laboratories' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Divis Laboratories volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Divis Laboratories correlated with the market. If Beta is less than 0 Divis Laboratories generally moves in the opposite direction as compared to the market. If Divis Laboratories Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Divis Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Divis Laboratories is generally in the same direction as the market. If Beta > 1 Divis Laboratories moves generally in the same direction as, but more than the movement of the benchmark.
Divis Laboratories Limited Total Assets Over Time
Divis Laboratories December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Divis Laboratories help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Divis Laboratories Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Divis Laboratories Limited based on widely used predictive technical indicators. In general, we focus on analyzing Divis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Divis Laboratories's daily price indicators and compare them against related drivers.
| Downside Deviation | 0.9885 | |||
| Information Ratio | 0.1144 | |||
| Maximum Drawdown | 9.79 | |||
| Value At Risk | (1.55) | |||
| Potential Upside | 3.37 |
Complementary Tools for Divis Stock analysis
When running Divis Laboratories' price analysis, check to measure Divis Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Divis Laboratories is operating at the current time. Most of Divis Laboratories' value examination focuses on studying past and present price action to predict the probability of Divis Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Divis Laboratories' price. Additionally, you may evaluate how the addition of Divis Laboratories to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |